MEDIPHARM LABS CORP (LABS.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:LABS - CA58504D1006 - Common Stock
0.07 CAD
0 (0%)
Taking everything into account, LABS scores 2 out of 10 in our fundamental rating. LABS was compared to 34 industry peers in the Pharmaceuticals industry. LABS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, LABS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- LABS had negative earnings in the past year.
- In the past year LABS has reported a negative cash flow from operations.
- LABS had negative earnings in each of the past 5 years.
- In the past 5 years LABS always reported negative operating cash flow.
1.2 Ratios
- LABS's Return On Assets of -17.22% is on the low side compared to the rest of the industry. LABS is outperformed by 61.76% of its industry peers.
- Looking at the Return On Equity, with a value of -21.20%, LABS is in line with its industry, outperforming 47.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.22% | ||
| ROE | -21.2% | ||
| ROIC | N/A |
ROA(3y)-28.72%
ROA(5y)-40.33%
ROE(3y)-34.34%
ROE(5y)-50.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of LABS (25.87%) is worse than 61.76% of its industry peers.
- LABS's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for LABS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 25.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-3.36%
2. Health
2.1 Basic Checks
- LABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, LABS has more shares outstanding
- The number of shares outstanding for LABS has been increased compared to 5 years ago.
- The debt/assets ratio for LABS has been reduced compared to a year ago.
2.2 Solvency
- LABS has an Altman-Z score of -2.12. This is a bad value and indicates that LABS is not financially healthy and even has some risk of bankruptcy.
- LABS has a worse Altman-Z score (-2.12) than 67.65% of its industry peers.
- LABS has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
- LABS has a better Debt to Equity ratio (0.01) than 82.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.12 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
- LABS has a Current Ratio of 3.20. This indicates that LABS is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 3.20, LABS belongs to the top of the industry, outperforming 82.35% of the companies in the same industry.
- A Quick Ratio of 2.27 indicates that LABS has no problem at all paying its short term obligations.
- The Quick ratio of LABS (2.27) is better than 85.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.2 | ||
| Quick Ratio | 2.27 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 22.50% over the past year.
- LABS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.06%.
- LABS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.15% yearly.
EPS 1Y (TTM)22.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)18.06%
Revenue growth 3Y24.58%
Revenue growth 5Y-20.15%
Sales Q2Q%24.7%
3.2 Future
- The Earnings Per Share is expected to grow by 36.84% on average over the next years. This is a very strong growth
- Based on estimates for the next years, LABS will show a quite strong growth in Revenue. The Revenue will grow by 14.57% on average per year.
EPS Next Y54.1%
EPS Next 2Y36.84%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.37%
Revenue Next 2Y14.57%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for LABS. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LABS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- LABS's earnings are expected to grow with 36.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.84%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for LABS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MEDIPHARM LABS CORP / LABS.CA FAQ
What is the ChartMill fundamental rating of MEDIPHARM LABS CORP (LABS.CA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to LABS.CA.
What is the valuation status for LABS stock?
ChartMill assigns a valuation rating of 1 / 10 to MEDIPHARM LABS CORP (LABS.CA). This can be considered as Overvalued.
How profitable is MEDIPHARM LABS CORP (LABS.CA) stock?
MEDIPHARM LABS CORP (LABS.CA) has a profitability rating of 0 / 10.